

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



TYK Medicines, Inc

浙江同源康醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2410)

VOLUNTARY ANNOUNCEMENT

RESEARCH RESULTS FOR FIVE INNOVATIVE DRUG PROJECTS WILL BE PRESENTED AT 2026 AACR ANNUAL MEETING

This announcement is made by TYK Medicines, Inc (浙江同源康醫藥股份有限公司) (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business developments of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the research progress and results for five innovative drug projects under development of the Company, namely TY-0609 (CDK4 inhibitor), TY-2699a (CDK7 inhibitor), TY-2719 (EGFR/FAK (PROTAC) inhibitor), PI3K α (PI3K α inhibitor), and TY-1054 (YAP-TEAD inhibitor), will be presented by the Company in poster presentation at 2026 American Association for Cancer Research (“**AACR**”) annual meeting. The five projects to be presented are all innovative anti-tumor small molecule drug candidates independently developed by the Company. The 2026 AACR annual meeting will be held from April 17 to 22, 2026, in San Diego, USA, and the Company’s posters will be exhibited from April 19 to April 21, 2026, respectively. For more details, please visit the Company’s website at www.tykmedicines.com (the content of the website does not constitute part of this announcement).

ABOUT THE COMPANY

TYK Medicines is an international innovative biopharmaceutical company focusing on the research and development of next-generation kinase inhibitors to address unmet clinical needs in cancer treatment. Since its inception in 2017, TYK Medicines has developed more than ten innovative products, covering various stages from PCC to Phase III clinical trials. The Company is committed to providing patients with more effective and safer anti-tumor drugs.

FORWARD-LOOKING STATEMENT

The Company and the Company as referred to in this news make no representation or warranty, express or implied, as to the information released. Although the Company endeavors to ensure the accuracy of the information, it may contain inaccuracies or omissions. The information may not cover all relevant factors and different conclusions may be drawn due to different interpretation methods. Forecasts and opinions are speculative and are based on assumptions regarding future markets, customer behavior, and technological developments, and thus may be subject to significant errors. The information and opinions are as of the date of publication only and are subject to change at any time, and will not be updated for subsequent developments.

Neither the Company nor its affiliates, nor their respective directors, senior management, employees, consultants or representatives, shall be liable for any loss (including loss arising from negligence, misrepresentation, omission or otherwise) arising from the use of or reliance on the information herein, or any decision made based on such information.

TECHNICAL GLOSSARY

“CDK”	cyclin-dependent kinase
“EGFR”	epidermal growth factor receptor
“PROTAC”	proteolysis-targeting chimera
“YAP”	yes associated protein
“TEAD”	transcriptional enhanced associate domain

Warning under Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the relevant product will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
TYK Medicines, Inc
(浙江同源康醫藥股份有限公司)
Dr. WU Yusheng

Chairman, Executive Director and Chief Executive Officer

Hong Kong, March 25, 2026

As at the date of this announcement, the Board comprises Dr. WU Yusheng as executive Director, Dr. LI Jun, Dr. GU Eric Hong, Dr. JIANG Mingyu, Mr. HE Chao and Dr. ZHU Xiangyang as non-executive Directors, and Dr. LENG Yuting, Dr. XU Wenqing, Dr. SHEN Xiuhua and Mr. JIANG Xiaolin as independent non-executive Directors.